The MACBETH consortium provides a breakthrough technology for advanced downstream processing by combining catalytic synthesis with the corresponding separation units in a single highly efficient catalytic membrane reactor (CMR). This disruptive technology has the ability to reduce greenhouse gas emissions (GHG) of large volume industrial process by up to 45 %. Additionally, resource and energy efficiency will be increased by up to 70%. The revolutionary new reactor design will not only guarantee substantially smaller and safer production plants, but has also a tremendous competitive advantage since CAPEX is decreased by up to 50% and OPEX by up to 80%. The direct industrial applicabilty will be demonstrated by the long term operation of TRL 7 demo plants for the highly relevant and large scale processes: hydroformylation, hydrogen production, propane dehydrogenation. The confidence of the MACBETH consortium to reach its highly ambitious goals are underlined by two special extensions that go well beyond the ordinary scope of an EU project: 1) Transfer of CMR technology to biotechnology: Within MACBETH we will demonstrate that starting from building blocks of TRL 5 (not from a TRL 5 pilot plant), that fit the requirements of selective enzymatical cleavage of fatty acids with the combined support and system knowledge of the experienced CMR partners, a TRL 7 demo plant will be established and operated 2) Creation of the spin-off European “Lighthouse Catalytic Membrane Reactors” (LCMR) within MACBETH: A European competence center for CMR will be established already within the MACBETH project with an actual detailed business plan including partner commitment. These efforts will ultimately lead to the foundation of the “Lighthouse Catalytic Membrane Reactors” (LCMR) that will provide access to the combined knowledge of the MACBETH project .

The key objective of the GLAMOUR project is the design, scale-up and validation of an integrated process that converts the waste bio-based feedstock such as crude glycerol into aviation and marine diesel fuels. The focus of the project will be a combination of high pressure, auto-thermal reforming/gasification using chemical looping to produce syngas and the integration of Fischer-Tropsch compact reactor integrated with 3D printed structured catalyst. The GLAMOUR process will achieve full conversion of the crude glycerol into synthetic paraffine kerosene (FT-SPK) to be used as jetfuel and into marine diesel oil (MDO) with an energy efficiency of 65% and the remaining gas will be converted into pure CO2 stream (purity >95%) and extra heat available. These improvements would increase the overall revenue of existing 2nd generation bio-diesel plants reducing the cost for large scale biomass-to-liquid production processes by 35% and the CO2 emissions up to 70%. The project will focus on the scale up of the two processes to achieve a final TRL5 demonstration for 1000 hours by using 2 kg/h of glycerol in a packed bed chemical looping systems and a downstream FT reactor. The consortium includes two universities, three large research centres and 5 industries (including SMEs) which will combine fundamental knowledge on gas-solid and catalytic reactions, material design and engineering process design, economics, environmental analysis, societal and policy making decision. In the long term, GLAMOUR could unlock low cost feedstock with cost decrease of 65%, increase the production of biofuel to achieve the overall bio-jet fuel production to move 19% of the EU passengers reducing the CO2 emissions up to 27 Mt/year and generating a scalable business up to 11 bln/years.

Digital healthcare may prevent poor health. Personalised early risk prediction by artificial intelligence can empower citizens to adopt healthier habits and a better lifestyle. This project aims at defining a general personalised early risk prediction model that will be used to support individual preventive measures as well as early intervention. New digital tools are designed to empower both citizens and patients. Furthermore, the impact of the new digital tools on health and care pathways are investigated. Three main scenarios are included: 1. Chronic sun damage and the fight against skin cancer, 2. The late complications of diabetes mellitus and 3. The four main lifestyle risk factors in noncommunicable diseases. In scenario 1, a smartphone application estimates a person`s risk for sun damage and skin cancer. Both healthy persons and skin cancer patients are included. The analysis is based on user-collected data indicating previous and current sun exposure, skin type including a computer-based naevus classification and the family history of skin cancer. Persons at increased risk are educated on healthy sun exposure behaviour including sun screen use. In addition, they are asked to see their doctor for a total body skin examination. In scenario 2, a smartphone application estimates a person`s risk for late complications of diabetes. General lifestyle measures as well as blood sugar levels collected by the patient are used as input for the analysis. Persons at increased risk for complications are given specific advice and are asked to see their doctor. In scenario 3, a web-based tool to collect general lifestyle data in healthy populations is tested, emphasising the four main risk factors: Unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. All data in the project are analysed in a multidisciplinary approach including medical, sociological and behavioural outcomes.

The platform chemicals sector is currently highly dependent on fossil-fuels. The small volumes of current biobased platform chemicals are reliant on sugar/starch/oil crops which diverts them from food uses and there are also high environmental impacts linked with their land-use and supply cycles. Lignocellulosic feedstocks, particularly residues, are more sustainable but to date the range of chemicals that have been demonstrated at-scale from these has been limited. In particular, there are a range of functionalities associated with fossil-derived platform chemicals that current biobased chemicals cannot replicate. BIONEER addresses this issue by demonstrating production of a new range of carbohydrate-derived building blocks and platform chemicals at TRL6/7. A selection of additional functionalities obtained through carefully controlled optimised modifications and involving both chemical and enzymatic approaches are conferred to the new building blocks that, for the first time at-scale, allow for the mass-market substitution of fossil-derived chemicals in a range of application markets. BIONEER builds on the TRL4/5 advances made in the development of resource and energy-efficient processes for the production of these building blocks in prior projects. The BIONEER consortium and advisory board covers all stages of the value cycle, ranging from the sourcing of sustainable feedstocks to the extraction and modification of biomass fractions, leading to the production of building blocks that are then application tested in the UV-cured-coatings and personal care sectors by industrial partners. Safety and sustainability aspects are integral to BIONEER, which follows, and seeks to improve, the EU’s safe-and-sustainable-by-design (SSbD) framework. It is expected, due to the involvement of key technology developers and industrial partners, that the BIONEER technologies will be rapidly commercialised post-project.

ONCOVALUE will unlock the full potential of real world data (RWD) collected in European cancer hospitals and institutes to ease the decision-making of regulators on cost-effectiveness of novel cancer therapies. To achieve this, we build up data collection and processing capabilities of leading European cancer hospitals to create a high-quality clinical, quality of life, and adverse events data-sources. With the use powerful AI technologies, we will transform unstructured data originating from medical notes and medical images into structured data to enable analytics and real world evidence (RWE). This RWE will be directly available for clinicians for treatment management and for health regulatory and HTA bodies to adopt optimized data-driven methodologies for the effective assessment of medicinal products and digital health innovations. For that, we will provide an end-to-end infrastructure for RWD reporting in health regulatory and HTA decision-making and address the legal constraints in the cancer hospitals to ensure secure and legal access to RWD. Furthermore, ONCOVALUE will ensure the implementation of the developed guidelines and methodologies, by providing trainings for the collection and management of high-quality RWD in European cancer centres and for the analysis of this data by HTA and regulatory bodies. By opening the door to widespread regulatory and HTA integration of RWD, ONCOVALUE will lead to safer, more efficient, and affordable therapies, technologies, and digital solutions for (personalised) cancer care. As such, ONCOVALUE is positioned to contribute to increased cost-effectiveness and subsequent sustainability of cancer care. Systematic collection and evaluation of the patient reported outcomes will lead to improved well-being of the patients. Subsequently, on the long-term implementation of value-based cancer care at European cancer hospitals will aid in reducing the growing burden of cancer treatment in the EU and worldwide.